-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
<>
In September 2021, Eisai began rolling submission of lecanemab's Biologics Licensing Application (BLA) to the FDA according to the accelerated approval channel
The phase 3 clinical study of lecanemab Clarity AD for early AD is underway, and recruitment was completed in March 2021, with a total of 1,795 patients
Alzheimer's disease is a serious, progressive, and devastating disease with few treatment options